Stocks and Investing
Stocks and Investing
Mon, June 12, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Joseph Pantginis Maintained (APTO) at Strong Buy with Increased Target to $23 on, Jun 12th, 2023
Joseph Pantginis of HC Wainwright & Co., Maintained "Aptose Biosciences Inc." (APTO) at Strong Buy with Increased Target from $12 to $23 on, Jun 12th, 2023.
Joseph has made no other calls on APTO in the last 4 months.
There are 3 other peers that have a rating on APTO. Out of the 3 peers that are also analyzing APTO, 0 agree with Joseph's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Joseph
- Edward Tenthoff of "Piper Sandler" Maintained at Buy with Decreased Target to $37 on, Wednesday, June 7th, 2023
- Gregory Renza of "RBC Capital" Maintained at Buy with Decreased Target to $40 on, Wednesday, June 7th, 2023
- Carey Macrury of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $120 on, Monday, March 27th, 2023
Contributing Sources